Praxis Precision Medicines (NASDAQ:PRAX) Hits New 52-Week High – What’s Next?

22 Dec 2025, 15:15 by Amy Steele · The Cerbat Gem

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $283.29 and last traded at $282.0950, with a volume of 130641 shares traded. The stock had previously closed at $272.92.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PRAX shares. Deutsche Bank Aktiengesellschaft set a $313.00 price target on shares of Praxis Precision Medicines in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Praxis Precision Medicines in a research note on Monday, December 15th. Oppenheimer restated an “outperform” rating and issued a $750.00 price objective (up previously from $250.00) on shares of Praxis Precision Medicines in a research note on Monday, December 15th. UBS Group set a $750.00 target price on Praxis Precision Medicines in a research report on Monday, December 15th. Finally, Lifesci Capital raised Praxis Precision Medicines to a “strong-buy” rating in a report on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $403.80.

Get Our Latest Stock Report on Praxis Precision Medicines

Praxis Precision Medicines Price Performance

The business’s 50 day simple moving average is $193.66 and its 200 day simple moving average is $99.24. The company has a market capitalization of $7.09 billion, a price-to-earnings ratio of -21.93 and a beta of 2.95.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.45) by $0.09. As a group, analysts expect that Praxis Precision Medicines, Inc. will post -10.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Alex Nemiroff sold 25,130 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $193.09, for a total value of $4,852,351.70. Following the transaction, the general counsel directly owned 20,832 shares in the company, valued at $4,022,450.88. This trade represents a 54.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Lauren Mastrocola sold 13,600 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total transaction of $2,612,288.00. Following the completion of the transaction, the insider directly owned 10,442 shares in the company, valued at $2,005,699.36. This represents a 56.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.70% of the company’s stock.

Institutional Trading of Praxis Precision Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in PRAX. Vanguard Group Inc. increased its holdings in shares of Praxis Precision Medicines by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 1,087,020 shares of the company’s stock valued at $41,165,000 after purchasing an additional 23,381 shares in the last quarter. Swiss National Bank grew its position in shares of Praxis Precision Medicines by 3.8% in the first quarter. Swiss National Bank now owns 27,100 shares of the company’s stock valued at $1,026,000 after purchasing an additional 1,000 shares during the last quarter. Nuveen LLC acquired a new position in shares of Praxis Precision Medicines during the 1st quarter worth approximately $559,000. Algert Global LLC purchased a new stake in shares of Praxis Precision Medicines during the first quarter worth about $814,000. Finally, Walleye Capital LLC increased its stake in Praxis Precision Medicines by 47.0% in the first quarter. Walleye Capital LLC now owns 131,756 shares of the company’s stock valued at $4,990,000 after purchasing an additional 42,143 shares during the last quarter. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Praxis Precision Medicines Company Profile

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.